


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199179</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1942-0870</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>mAbs</Title>
                <ISOAbbreviation>MAbs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>L<sup>445</sup>P mutation on heavy chain stabilizes IgG<sub>4</sub> under acidic conditions.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/19420862.2019.1631116</ELocationID>
            <Abstract>
                <AbstractText>IgG<sub>4</sub>, a common type of therapeutic antibody, is less stable during manufacturing processes compared with IgG<sub>1</sub>. Aggregation and fragmentation are the two main challenges. Here, we report instability of the heavy chain (HC) C-terminal region under acidic conditions, which leads to cleavage and aggregation. Leu<sup>445</sup>, at the C-terminal region of the HC in IgG<sub>4,</sub> plays a critical role in its acid-induced fragmentation and subsequent aggregation. We found that mutating HC C-terminal Leu<sup>445</sup> to Pro (the corresponding residue in IgG1) in IgG<sub>4</sub>_CDR-X significantly reduces fragmentation and aggregation, while mutating Pro<sup>445</sup> to Leu in IgG<sub>1</sub>_CDR-X promotes fragmentation and aggregation. HC C-terminal Gly<sup>446</sup> cleavage was observed in low pH citrate buffer and resulted in further fragmentation and aggregation, whereas, glycine buffer can completely inhibit the cleavage and aggregation. It is proposed that cleavages occur through acid-induced hydrolysis under acidic conditions and glycine stabilizes IgG<sub>4</sub> via two main mechanisms: 1) product feedback inhibition of the hydrolysis reaction, and 2) stabilization of protein conformation by direct interaction with the peptide backbone and charged side chains. Experiments using IgG<sub>4</sub> molecules IgG<sub>4</sub>_CDR-Y and IgG<sub>4</sub>_CDR-Z with the same CH domains as IgG<sub>4</sub>_CDR-X, but different complementarity-determining regions (CDRs), indicate that the stability of the HC C-terminal region is also closely related to the sequence of the CDRs. The stability of IgG<sub>4</sub>_CDR-X is significantly improved when binding to its target. Both observations suggest that there are potential interactions between Fab and CH2-CH3 domains, which could be the key factor affecting the stability of IgG antibodies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Chang-Ai</ForeName>
                    <Initials>CA</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3587-2215</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Andrew Z</ForeName>
                    <Initials>AZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Chemistry Department , University of Massachusetts Lowell , 1 University Ave., Lowell , MA , 01854.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramineni</LastName>
                    <ForeName>Charan K</ForeName>
                    <Initials>CK</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2251-1787</Identifier>
                    <AffiliationInfo>
                        <Affiliation>b Chemistry Department , University of Massachusetts Lowell , 1 University Ave., Lowell , MA , 01854.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wallace</LastName>
                    <ForeName>Matt</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4874-9075</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Culyba</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2812-764X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guay</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3468-942X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehta</LastName>
                    <ForeName>Kinjal</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1926-4263</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mabry</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4756-9021</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>c Current affiliation: Global Biologics , Takeda, 35 Landsdowne St, Cambridge , MA 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farrand</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0406-9139</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Chemistry Department , University of Massachusetts Lowell , 1 University Ave., Lowell , MA , 01854.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Jianwen</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1073-0704</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Jounce Therapeutics , 780 Memorial Dr., Cambridge , MA , 02139.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>d Current affiliation: MassBiologics , University of Massachusetts Medical School , 460 Walk Hill St. Mattapan , MA 02126.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>MAbs</MedlineTA>
            <NlmUniqueID>101479829</NlmUniqueID>
            <ISSNLinking>1942-0862</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">C-terminal cleavage</Keyword>
            <Keyword MajorTopicYN="N">acidic stress</Keyword>
            <Keyword MajorTopicYN="N">antibody</Keyword>
            <Keyword MajorTopicYN="N">domain interaction</Keyword>
            <Keyword MajorTopicYN="N">mutation</Keyword>
            <Keyword MajorTopicYN="N">stability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199179</ArticleId>
            <ArticleId IdType="doi">10.1080/19420862.2019.1631116</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

